Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation

Tumor Biology

Volumn 31, Issue 4, 2010, Pages 287-295

  Zheng, Tongsen ^a   Wang, Jiabei ^a   Chen, Xi ^a   Meng, Xianzhi ^a   Song, Xuan ^a   Lu, Zhaoyang ^a   Jiang, Hongchi ^a   Liu, Lianxin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cholangiocarcinoma; Gemcitabine; MDM2; Nutlin 3; P73

Indexed keywords

CASPASE 3; CASPASE 9; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUTLIN 3; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; PROTEIN P73; PUMA PROTEIN; SMALL INTERFERING RNA; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DNA BINDING PROTEIN; DRUG DERIVATIVE; IMIDAZOLE DERIVATIVE; MDM2 PROTEIN, HUMAN; MESSENGER RNA; NUCLEAR PROTEIN; PIPERAZINE DERIVATIVE; TP53 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CARCINOMA CELL; CELL GROWTH; CELL NUCLEUS; CELL NUCLEUS INCLUSION BODY; CELL PROLIFERATION; CELL SURFACE; CHROMATIN CONDENSATION; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; ELECTRON MICROSCOPY; ENZYME ACTIVATION; FILOPODIUM; FLOW CYTOMETRY; GENE MUTATION; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MICROVILLUS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECRETORY VESICLE; WESTERN BLOTTING; BILE DUCT TUMOR; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; GENETICS; MUTATION; PATHOLOGY; TUMOR CELL CULTURE;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BILE DUCT NEOPLASMS; BLOTTING, WESTERN; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; DNA-BINDING PROTEINS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; IMIDAZOLES; IMMUNOPRECIPITATION; MUTATION; NUCLEAR PROTEINS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 77954646472     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-010-0035-7     Document Type: Article

References (25)

1. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366(9493):1303-14.
2. Thongprasert S. The role of chemotherapy in cholangiocarcinoma. Ann Oncol. 2005;16 Suppl 2:ii93-6.
3. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, FiebigerW, Lenauer A, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol. 2001;12(2):183-6.
4. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin Jr WG. Chemosensitivity linked to p73 function. Cancer Cell. 2003;3(4):403-10.
5. Briggs CD, Neal CP, Mann CD, Steward WP, Manson MM, Berry DP. Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur J Cancer. 2009;45(1):33-47.
6. Tannapfel A, Engeland K, Weinans L, Katalinic A, Hauss J, Mössner J, et al. Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. Br J Cancer. 1999;80(7):1069-74.
7. Lau LM, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene. 2008;27(7):997-1003.
8. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med. 2007;13(1):23-31.
9. Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, Vercruysse L, et al. Antitumor activity of the selective MDM2 antagonist Nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Instf. 2009;101(22):1562-74.
10. Peirce SK, Findley HW. High level MycN expression in non- MYCN amplified neuroblastoma is induced by the combination treatment Nutlin-3 and doxorubicin and enhances chemosensitivity. Oncol Rep. 2009;22(6):1443-9.
11. Hasegawa H, Yamada Y, Iha H, Tsukasaki K, Nagai K, Atogami S, et al. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells. Leukemia. 2009;23(11):2090-101.
12. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303(5659):844-8.
13. Kojima Y, Honda K, Hamada H, Kobayashi N. Oncolytic gene therapy combined with double suicide genes for human bile duct cancer in nude mouse models. J Surg Res. 2009;157(1): e63-70.
14. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and Web site. Br J Cancer. 2004;91(2):355-8.
15. Picariello L, Carbonell Sala S, Martineti V, Gozzini A, Aragona P, Tognarini I, et al. A comparison of methods for the analysis of low abundance proteins in desmoid tumor cells. Anal Biochem. 2006;354(2):205-12.
16. Mai Z, Blackburn GL, Zhou JR. Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in mice. Carcinogenesis. 2007;28:1217-23.
17. Wang D, Wang Z, Tian B, Li X, Li S, Tian Y. Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs. Int J Urol. 2008;15:435-41.
18. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
19. Chen M, Hough AM, Lawrence TS. The role of p53 in gemcitabine -mediated cytotoxicity and radiosensitization. Cancer Chemother Pharmacol. 2000;45(5):369-74.
20. Galmarini CM, Clarke ML, Falette N, Puisieux A, Mackey JR, Dumontet C. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer. 2002;97 (4):439-45.
21. Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X, et al. MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol. 1999;19(5):3257-66.
22. Della Torre G, Pasquini G, Pilotti S, Alasio L, Civelli E, Cozzi G, et al. TP53 mutations and MDM2 protein overexpression in cholangiocarcinomas. Diagn Mol Pathol. 2000;9(1):41-6.
23. Chen X, Zhang M, Liu LX. The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells. Oncol Rep. 2009;22(1):73-80.
24. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 2001;7(3):683-94.
25. Alsafadi S, Tourpin S, André F, Vassal G, Ahomadegbe JC. P53 family: at the crossroads in cancer therapy. Curr Med Chem. 2009;16(32):4328-44.